Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

08-06-2020 | ASCO 2020 | Conference coverage | Video

Expert highlights: Targeted therapy for ALK-, RET- and MET-driven NSCLC

Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

28-04-2020 | AACR 2020 | News

Capmatinib shows potential for treatment of MET-driven NSCLC

29-09-2017 | Non-small-cell lung cancer | ESMO 2017 | News

ALUR, ALEX results cement alectinib as advanced ALK-positive NSCLC standard of care

13-06-2019 | Non-small-cell lung cancer | Conference coverage | News

BLU-667 active against RET fusion-positive advanced NSCLC

12-09-2019 | Non-small-cell lung cancer | Conference coverage | News

LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC
Image Credits